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Original Article
An Albumin-Oligonucleotide Assembly
for Potential Combinatorial Drug Delivery
and Half-Life Extension Applications
Matthias Kuhlmann,1 Jonas B.R. Hamming,1 Anders Voldum,1 Georgia Tsakiridou,1 Maja T. Larsen,1
Julie S. Schmøkel,1 Emil Sohn,1 Konrad Bienk,1 David Schaffert,1 Esben S. Sørensen,1 Jesper Wengel,2
Daniel M. Dupont,1 and Kenneth A. Howard1
1Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, Aarhus University, 8000 Aarhus C, Denmark; 2Nucleic Acid Center,
Department of Physics, Chemistry, and Pharmacy, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark
The long blood circulatory property of human serum albumin,
due to engagement with the cellular recycling neonatal Fc re-
ceptor (FcRn), is an attractive drug half-life extension enabling
technology. This work describes a novel site-speciﬁc albumin
double-stranded (ds) DNA assembly approach, in which the
30 or 50 end maleimide-derivatized oligodeoxynucleotides are
conjugated to albumin cysteine at position 34 (cys34) and an-
nealed with complementary strands to allow single site-speciﬁc
protein modiﬁcation with functionalized ds oligodeoxynucleo-
tides. Electrophoretic gel shift assays demonstrated successful
annealing of complementary strands bearing Atto488, 6-car-
boxyﬂuorescein (6-FAM), or a factor IXa aptamer to the
albumin-oligodeoxynucleotide conjugate. A ﬂuorometric fac-
tor IXa activity assay showed retained aptamer inhibitory activ-
ity upon assembly with the albumin and completely blocked
factor IXa at a concentration of 100 nM for 2 hr. The assembled
construct exhibited stability in serum-containing buffer and
FcRn engagement that could be increased using an albumin
variant engineered for higher FcRn afﬁnity. This work presents
a novel albumin-oligodeoxynucleotide assembly technology
platform that offers potential combinatorial drug delivery
and half-life extension applications.
INTRODUCTION
Site-speciﬁc delivery and target engagement are prominent determi-
nants of the therapeutic efﬁcacy of drugs.1 Molecular medicines,
such as RNA-interference-2,3 and aptamer-based1,4–7 therapeutics
offer unprecedented target speciﬁcity; however, susceptibility to
nuclease degradation and rapid renal clearance require enabling tech-
nologies to realize the clinical potential. Although chemical modiﬁca-
tions, such as 20-sugar (20-ﬂuoro, 20-O-methyl, etc.)6 or locked nucleic
acids,8 have overcome stability issues, alternative blood half-life
extension technologies are needed to overcome drawbacks associated
with poly(ethylene glycol) (PEG), such as non-degradability and
possible immune induction.9–11 PEG immunogenicity, for example,
was recently suggested to be the cause of the serious allergic reactions
observed with an aptamer-based anticoagulant system targeting fac-
tor IX (REG1) in the RADAR phase 2b clinical trial.12,13
Human serum albumin (HSA) is an attractive drug delivery plat-
form due to its long-circulatory half-life of 19 days,14 facilitated
by engagement with the cellular recycling neonatal Fc receptor
(FcRn).15,16 This property has been exploited in marketed albumin-
binding drugs, such as Levemir and Victoza, that reversibly associate
with the endogenous albumin pool.10,17,18 Albumin is structurally
divided into three domains, with domain III (DIII) playing the major
role in FcRn binding19 and domain I (DI) containing a single free
thiol at position 34 (cys34). Site-speciﬁc covalent conjugation of drugs
to endogenous HSA or preconjugation to recombinant human albu-
min (rHA) at position cys34 is, therefore, an attractive strategy for
maintained FcRn engagement.20 Kratz et al.21 have exploited site-spe-
ciﬁc maleimide-based drug conjugation for attachment of doxoru-
bicin to the endogenous HSA pool. A limitation of conjugation to
the single free thiol of endogenous HSA or rHA, however, is the
inability for loading at a ﬁnal drug:albumin ratio greater than 1:1.22
Although conjugation to albumin’s multiple surface lysines may over-
come this caveat, the absence of site selectivity may compromise FcRn
engagement and concomitant albumin pharmacokinetics.
Oligodeoxynucleotides (ODNs) have found wide applications in
fundamental research and as potential therapeutics.23,24 The high
speciﬁcity of base pairing allows engineering of complex DNA struc-
tures in a controlled manner that has fueled the emerging ﬁeld of
DNA nanotechnology.25,26 We propose site-speciﬁc conjugation of
ODN with the single thiol of rHA at cys34 (referred to as rHAODN)
in conjunction with complementary strand (cODN) annealing for
introduction of up to three (different) functionalities using the
ODN termini (Figure 1). This versatile strategy allows the potential
drug loading of ODN and cODN precursors prior to rHA conjugation
and cODN annealing. This systemmay have the potential to combine
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the target speciﬁcity of aptamers with the long circulatory half-life
of albumin for next-generation molecular medicines. As proof-of-
concept, rHAODN conjugates were annealed with various cODN
variants (rHAODN//cODN) to generate constructs that were specif-
ically labeled with or without ﬂuorophores at different positions of the
resulting double strand (dsODN) to demonstrate robust assembly in-
dependent of the ODN orientation (50 to 30 or 30 to 50) and function-
alization position (ODN or cODN). The rHAODN conjugate was
further annealed with a cODN-bearing factor IXa (FIXa)-blocking
aptamer, producing a construct (rHAODN//apt) that exhibited
retained aptamer activity and FcRn engagement and high stability
in serum-containing buffer, prerequisites for potential therapeutic
applications.
RESULTS
The ODN sequences and code numbers used in this work are
included in Table S1.
Maleimide Functionalization of ODN
Maleimide functionalization (“activation”) of ODN 50 end or 30 end
amines was optimized by varying the pH and reaction time using a
commercial succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-
carboxylate (SMCC) linker. Urea gel electrophoresis and band inten-
sity quantiﬁcation (exempliﬁed with ODN1; Figure 2) revealed
optimal activation yields after 16–24 hr at a slightly elevated pH
(HEPES, pH 8), with an excess of SMCC (SMCC:ODN1 = 50:1).
Oligonucleotide activation was similarly efﬁcient for the other
ODNs, irrespective of sequence, the position of the amine, and
whether or not a ﬂuorophore was attached (exempliﬁed with
ODN2, ODN3, and ODN8*; Figure S1). Reverse-phase high-perfor-
mance liquid chromatography (RP-HPLC) puriﬁcation (exempliﬁed
with ODN4*; Figure S2) veriﬁed the optimal activation conditions,
and a yield of more than 50% activated ODN was obtained for a
16-hr reaction at pH 8. Subsequent urea-PAGE gel analysis was
used to conﬁrm the identity of the puriﬁed products (exempliﬁed
Figure 1. Schematic Representation of Albumin-
Oligonucleotide Assembly
cODN precursors can be loaded with drugs (e.g., ap-
tamers) or functional groups before complementary an-
nealing to a rHAODN conjugate for potential combinatorial
functions or multiple drug delivery approaches. In addition,
an additional functionality can be attached to the free ODN
termini.
with ODN1; Figure S3). RP-HPLC-puriﬁed
SMCC-ODNs were desalted and freeze dried
and stock solutions were prepared in nuclease-
free water or buffer for further experiments.
rHA Conjugation to SMCC-Activated ODNs
Conjugation of rHAwith SMCC-ODN (at a ratio
of 1:1) was performed in HEPES buffer (pH 7.0)
at room temperature (RT). After 2 hr, SDS gel
electrophoresis analysis showed conjugation by both nucleic acid
staining (exempliﬁed with ODN3; Figure 3A, upper panel) and rHA
staining (Figure 3A, lower panel). Detection of both residual free
rHA and the rHAODN3 conjugate by MALDI-ToF analysis
conﬁrmed the conjugation (Figure 3B). Two different batches of
ODN3 were activated with SMCC (in Figure 3 denoted as SMCC-
ODN3 a and SMCC-ODN3 b) and conjugated to rHA in order
to show batch-to-batch reproducibility. In contrast, non-activated
ODN3 did not react with rHA (Figure 3A, lane 4). Conjugation was
repeated with an SMCC-activated 6-carboxyﬂuorescein (6-FAM)-
labeled ODN (Table S1, ODN4*) to demonstrate the possibility of
exploiting the available 30 end of the ODN for functionality introduc-
tion, e.g., a ﬂuorescent probe, to the albumin-oligo assembly. Coomas-
sie protein staining and ﬂuorophore detection of 6-FAM-labeled
rHAODN4* conﬁrmed the conjugation (Figure S4). Furthermore, it
was shown that a 30-SMCC-activated ODN (ODN2; Figure S5) reacts
similarly efﬁciently with rHA compared to 50-SMCC-activatedODNs.
Ellman’s assay analysis of the rHA stock detected 54% free thiols
and, therefore, even with complete ODN conjugation to all available
cys34 thiols in the preparation, free rHA is expected to be present after
the reaction. Protein band intensity quantiﬁcation of the rHA:SMCC-
ODN4* reaction (Figure S4) revealed 55%–65% conjugation that
correlated with Ellman’s determination, showing high reactivity of
the available cys34 toward activated ODNs.
rHAODN conjugates were puriﬁed from residual rHA using ion-ex-
change chromatography (IEX). The high negative charge introduced
by ODN conjugation shifted the retention time to 48.6 min for the
conjugate compared to 30 min for pure rHA (Figure S6). The
collected conjugate fractions were desalted, freeze dried, and dis-
solved in nuclease-free water. Direct quantiﬁcation of the rHAODN
concentration using UV spectroscopy could not be performed
because both ODN and rHA absorption spectra overlap (not shown).
A Bradford assay was, therefore, used to determine the rHAODN
conjugate concentration calibrated with pure rHA. A yield of only
www.moleculartherapy.org
Molecular Therapy: Nucleic Acids Vol. 9 December 2017 285
10% for the puriﬁed conjugate was obtained; the puriﬁcation process,
therefore, requires further investigation and optimization.
Annealing of rHAODN with cODN
To evaluate annealing speciﬁcity, Atto488-labeled complementary
cODN5* was assembled with either the rHAODN3 or the rHAODN6
conjugate in 0.1 M HEPES buffer (pH 7.0) overnight at RT. Incuba-
tion of the conjugate rHAODN6 with cODN5*, which both have the
same oligonucleotide sequence, showed no indication of non-speciﬁc
annealing (Figure 4, lane 1, 3, and 5; negative control [nc]). For as-
sembly of the rHAODN3//cODN5* construct containing a comple-
mentary ODN:cODN set, different rHAODN3:cODN5* ratios were
used (1:0.5 [Figure 4, lane 2], 1:1 [Figure 4, lane 4], and 1:2 [Figure 4,
lane 6]) and the band intensities of rHAODN3 and the annealed
construct (rHAODN3//cODN5*) were analyzed (Figure 4, protein
staining). Relative to the experiment with a two-fold excess of
cODN5* (rHAODN3:cODN5* = 1:2, [Figure 4, lane 6]), a product
yield of 60%–65% (1:0.5) and 90%–95% (1:1) was observed. Hence,
further excess of cODN would not dramatically increase product
yield.
To show that the rHAODN3 conjugate can also be annealed to a
cODN strand without a ﬂuorophore attached, we veriﬁed product
formation using cODN7, i.e., cODN5* without the ﬂuorophore
(rHAODN3//cODN7; Figure S7A). The results of annealing
rHAODN3 with cODN5* or ODN8* were included as a positive
and negative control, respectively. Finally, we wanted to demonstrate
that the annealing was independent of the ﬂuorophore being attached
to the rHA-conjugated ODN strand (“direct labeling”) or the
cODN strand annealed to rHAODN (“indirect labeling”). To verify
the direct labeling, 30-Atto488-labeled ODN8* was conjugated to
rHA (Figure S7B, Conj.*) and annealed with non-labeled cODN7
to produce the rHAODN8*//cODN7 construct.
Annealing of rHAODN with an FIXa-Blocking Aptamer
To allow conjugation of the aptamer with rHAODN3, the aptamer
was extended with the complementary DNA sequence to ODN3 in
the 30 end during synthesis (cODN-aptamer). The ﬁnal design of
the rHAODN//apt construct is shown in Figure S8. The sample was
puriﬁed post-annealing using size-exclusion chromatography (SEC)
with a ﬂow rate of 0.5 mL/min and PBS as the mobile phase (Fig-
ure S9). The collected construct fractions were concentrated using
centrifugal ﬁlters. Both SDS and native gel electrophoresis conﬁrmed
the efﬁcient removal of free aptamer and residual rHAODN upon
puriﬁcation (Figure S10). A BCA protein assay was performed using
a standard calibration with rHA to quantify the rHAODN//apt
construct. The samples were stored at 4C until further use. A con-
centration-dependent reduction in FIXa activity was observed at
rHAODN//apt construct solutions of 1–100 nM (Figure 5). The result
with the cODN-aptamer alone is shown in Figure S11. As a control, it
was shown that rHAODN itself did not inﬂuence the FIXa assay in the
presence of titrated amounts of rHAODN (Figure S12).
Human FcRn Affinity Studies
The ability of the rHAODN//apt construct to bind to human FcRn
(hFcRn) was investigated with biolayer interferometry using immobi-
lized hFcRn biosensors. Association and dissociation measurements
were performed at pH 5.5 to reﬂect the endosomal environment
needed to facilitate FcRn engagement,16 and regeneration of the
biosensor was performed at neutral pH 7.4 to reset the biosensor
and remove any hFcRn-bound material. The binding afﬁnities, KD,
were calculated based on a 1:1 binding model and the determined ki-
netic parameters kon and koff (Figure 6; Table 1). The assembled albu-
min-aptamer construct rHAODN//apt exhibited FcRn engagement;
however, the afﬁnity was reduced 9 compared to non-modiﬁed
rHA (KD 8.80 ± 2.17 mM and KD 0.98 ± 0.25 mM, respectively).
We, therefore, introduced a recombinant high-binding albumin
variant (HB)27 that has a higher hFcRn afﬁnity (KD 0.10 ±
0.008 mM) compared to wild-type rHA. Albumin-aptamer constructs
prepared with the HB albumin (HBODN//apt) demonstrated 30
higher hFcRn afﬁnity compared with wild-type rHAODN//apt (KD
0.28 ± 0.08 mM; Figures 6 and S13; Table 1) and at least 3 higher
afﬁnity to hFcRn than the non-modiﬁed wild-type rHA alone.
Stability of the rHAODN//apt Conjugate in Serum-Containing
Buffer
The rHAODN//apt construct and the FIXa aptamer were found to
exhibit the same degree of stability when incubated in 10% serum
for 12 and 24 hr at 37C and analyzed by agarose gel electrophoresis
(Figures 7A and 7B). Approximately 80% of the material was still
intact after 24 hr in both cases (Figure 7C). Over the course of
24 hr, the cODN-modiﬁed aptamer alone appeared to be partially di-
gested to a fragment migrating similarly to the naked FIXa aptamer
(Figure S14A). This is most likely due to digestion of the cODN
component when not engaged in the duplex of the rHAODN//apt
Figure 2. Activation of ODN with SMCC
(A) Urea gels were stained using SYBR gold and band intensity analysis used to
determine the activation efficiency. ODN1 (lower band) and SMCC-ODN1 (upper
band, activated) were observed. Increase of pH from 6.5 to 8.0 increased the yield
from 19% to 81% of activated ODN1 at 16 hr at room temperature. (B) Reactions at
pH 8.0 show that SMCC activation increased, with a prolonged reaction time from
1 hr to 24 hr.
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construct. rHA alone could not be visualized by SYBR GOLD staining
(data not shown), and the faint band observed for the rHAODN con-
jugate most likely originates from the staining of the ODN strand
(Figure S14B). This band also disappeared within 24 hr, suggesting
that, as for the DNA strand of the cODN-aptamer, the DNA strand
of rHAODN is also protected from digestion in the rHAODN//apt
construct. Hence, the rHAODN//apt assembly is stable in serum-con-
taining buffer.
DISCUSSION
Blood circulatory half-life extension technologies are required
to extend the therapeutic effect of drugs susceptible to rapid renal
clearance, such as RNAi- and aptamer-based molecular medicines.
PEGylation is an established drug half-life extension technique; how-
ever, concerns regarding tissue accumulation of non-biodegradable
high-molar mass PEG and complement activation have been
raised.9,11 HSAwith a blood circulatory half-life of19 days therefore
offers a biocompatible natural alternative.10,14 The pronounced circu-
latory half-life of HSA is predominately facilitated by engagement of
HSA with the cellular recycling FcRn.16,17 Control over site-speciﬁc
modiﬁcation on HSA is thought to be a prerequisite in order to main-
tain FcRn engagement with DIII that is the principal binding site of
HSA.19 The single free cys34 in DI is distant to the main FcRn-
engagement site in DIII and therefore offers an opportunity to conju-
gate drugs without compromising DIII interactions. This single site,
however, only allows monofunctionalization. In this work, we present
a cys34 site-speciﬁc albumin-dsDNA assembly approach to overcome
this issue, allowing addition of functionalities to the three free oligo
terminals.
Lau et al.28 described siRNA-albumin conjugation using the 30 end
amine-modiﬁed siRNA, which was activated with a commercial
NHS-maleimide linker (SMCC). The high speciﬁcity of the malei-
mide group toward thiols facilitated siRNA conjugation to the endog-
enous albumin pool, leading to a half-life extension from 5.1 ±
0.2 min to 75.9 ± 18.2 min in Sprague-Dawley rats.29 For our
Figure 3. Conjugation of ODN to rHA
(A) SDS gel electrophoresis of ODN3 conjugated to rHA
using maleimide chemistry. SYBR gold staining (upper
panel) and Coomassie staining (lower panel) confirm
conjugation to rHA of two different batches of ODN3
(SMCC-ODN3 a and SMCC-ODN3 b). (B) MALDI-ToF
analysis of rHAODN3 conjugate showing the unmodified
rHA at m/z = 66,590 and the conjugate rHAODN3 atm/z =
73,014 (calculated 73,360; MW(ODN3) = 6,550.4 g mol1
and MW(SMCC-ODN3) = 6,770.0 g mol1). MW, molec-
ular weight.
approach, either 50 or 30 end amine-modiﬁed
ODNs were modiﬁed with SMCC to allow
attachment of ODN-cODN pairs to albumin
in both orientations. Urea gel electrophoresis
analysis and RP-HPLC analysis showed a pH
and time-dependent trend for the efﬁciency of SMCC modiﬁcation
of ODNs, with maximum yields obtained using pH 8 and 16–24 hr
of incubation. The SMCC activation was investigated for both 30
and 50 end amine-modiﬁed ODNs, ODNs of different sequences,
and ODNs with or without a ﬂuorophore in the opposite end,
showing no obvious differences with respect to the efﬁciency of the
reaction.
The free thiol of rHA at position 34 is prone to Michael-addition
reactions on the maleimide-functional ODN.29 The available thiol
content of rHA was determined using an Ellman’s assay prior to
the conjugation of rHA with activated ODNs. Comparing the results
from the Ellman’s assay with the yields of ODN conjugation indicates
a quantitative Michael-addition for both the 50 and 30 end activated
ODNs. SMCC-unmodiﬁed ODN incubated with rHA showed no
band shift by gel electrophoresis that indicated absence of non-cova-
lent association of ODN with rHA. For rHAODN puriﬁcation in
our work, the large charge difference between residual rHA and
rHAODN promotes IEX as a suitable method. Unfortunately, due
to yet unknown reasons, after IEX and subsequent desalting, yields
of puriﬁed rHAODN were approximately 10%, which requires
improvements.
Annealing of rHAODN conjugates with cODN to form the
rHAODN//cODN assembled constructs was investigated and
conﬁrmed with ﬂuorophore-labeled ODN (direct labeling) as well
as ﬂuorophore-labeled cODN (indirect labeling). Hence, the assembly
of rHAODN//cODN constructs appears to be compatible with
loading of functionalities onto both the ODN and cODN, potentially
allowing combinatorial applications.
FIXa plays an important role in blood coagulation and is a target for
antithrombotic approaches. Currently available anticoagulants, how-
ever, can exhibit severe side effects, such as bleeding.5 Rusconi et al.4
described an aptamer-based FIXa inhibitor and an aptamer-blocking
complementary oligonucleotide antidote allowing for controllable
www.moleculartherapy.org
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therapy. An increased aptamer blood circulation was shown by the
same group using PEGylation.30 The application of PEG as a half-
life technology, however, may have drawbacks due to potential immu-
nogenicity and tissue accumulation.9,11 PEG immunogenicity was
indeed suggested to be the reason for early termination of the recent
phase 2b clinical trial with the FIXa aptamer antidote system
(REG1).12,13 In our work, the cODN-aptamer strand was designed
so that the aptamer was positioned at the opposite site to rHA along
the dsODN strand to reduce possible steric hindrance for annealing
and aptamer target engagement. Experiments revealed that the
cODN-aptamer strand could be successfully annealed to the
rHAODN conjugate. rHAODN could not completely be removed
by IEX, but elution time differences were sufﬁcient in SEC for puriﬁ-
cation of the rHAODN//apt construct from any residual rHAODN.
Aptamer activity after assembly with albumin was evaluated using a
FIXa activity assay kit based on the cleavage of a substrate by FXa.
FIXa activity measurements with the rHAODN//apt construct or
the cODN aptamer showed that both blocked FIXa activity
completely at a concentration of 100 nM, verifying that aptamer
activity is retained following annealing.
Our conjugation design is based on attachment of ODN to rHA at a
site distant from the region mainly responsible for FcRn engagement
to ensure retained circulatory half-life extension exploitation. The
rHAODN//apt construct exhibited FcRn engagement, although it
was 9 lower compared to non-modiﬁed rHA. Some interference
could be expected because aptamers are of considerable size
compared to proteins.31 Crystal structure32 and interaction analysis
studies33 have, however, also revealed an hFcRn/albumin binding
interface in the DI of albumin that is contributory toward optimal
binding. In addition, recent work in our laboratory showed a
decrease in albumin/hFcRn binding upon covalent attachment of
mPEG at cys34.34 To increase the FcRn afﬁnity of the aptamer-
albumin construct, a recombinant albumin variant engineered for
high FcRn binding (referred to as HB albumin) was introduced.
The HB albumin contains a single-point mutation in domain III,
triggering a stronger FcRn interaction and concomitant extended
half-life.27 The HB shows 10x higher afﬁnity toward hFcRn
compared to rHA (Table 1) and hence is a useful tool to rescue
the lost afﬁnity introduced by the annealed aptamer. Although ap-
tamer assembly with HB albumin (HBODN//apt) did reduce the
hFcRn afﬁnity of the HB albumin 3, the afﬁnity was improved
30 compared with rHAODN//apt and greater than rHA alone.
Hence, the compromised albumin-FcRn interaction caused by
aptamer albumin assembly could be re-established using the HB
albumin variant. This is in accordance with recent studies from
our laboratory showing that the reduction in hFcRn afﬁnity after
direct mPEG34 and aptamer Cys34 conjugation35 could be rescued
by using the HB variant.
Finally, we showed that the assembled aptamer-albumin construct
(including the dsDNA duplex) was stable in serum-containing buffer
over 24 hr at 37C to the same extent as the FIXa aptamer alone.
In this work, we present a novel albumin-ODN assembly method
based on cys34-selective conjugation of ODNs and subsequent an-
nealing of ﬂuorophore- and aptamer-modiﬁed cODN strands. This
versatile modular-based system offers potential blood circulatory
half-life extension applications and combinations of drug and
Figure 4. SDS Gel Electrophoresis Analysis of rHAODN3 and cODN5*
Annealing
The gel was stained for ODN/cODN detection with SYBR gold (nucleotide) and for
protein detection with Coomassie staining (protein). The labeled complementary
strand cODN5* was detected by Atto488 fluorescence. The fluorophore detection
and protein detection pictures were merged (merge). rHAODN6 and cODN5* an-
nealing experiments were used as non-specific annealing negative control (nc) as
ODN6 and cODN5* bear the same sequence. Annealing was performed with
rHAODN3:cODN5* ratios of 1:0.5, 1:1, and 1:2. Free rHA was not separated from
the rHAODN material before the analysis. The experiment represents one of three
independent similar experiments.
Figure 5. FIXa Activity Assay with rHAODN//apt
Substrate development (RFU) by FXa was monitored over time after incubation with
FIXa. Preincubation of FIXa with increasing concentrations of the rHAODN//apt
construct resulted in a lower activity of FXa (a reduced slope), indicating dose-
dependent inhibitory activity toward FIXa-mediated conversion of FX to FXa. The
figure shows the average and SDs of three experiments.
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imaging types. The presented platform design shows the capability
for three terminal functionalities; however, it also provides a frame-
work design to expand the diversity and quantity by insertion of
functionalized single nucleic acids or branching DNA structures as
described by Horn et al.36 or assemblies combining more than two
strands.37 The therapeutic aptamer constructs were stable in
serum-containing buffer and retained FcRn engagement, prerequi-
sites for potential in vivo applications.
MATERIALS AND METHODS
Materials
All ODNs with or without ﬂuorophores were purchased from DNA
Technology (Risskov, Denmark). ODNs were supplied as lyophilized
pellets and resuspended in nuclease-free water at 1 mM prior to use.
The concentration was validated by measuring A260 on a NanoDrop
ND1000. rHA (Albucult) was obtained from Sigma-Aldrich (Copen-
hagen, Denmark). Recombinant HB albumin (K573P) was kindly
provided by Albumedix (Nottingham, UK). SMCC was obtained
from Sigma-Aldrich and dissolved in dry DMSO at 100 mM prior
to use; aliquots were stored at 20C. Protogel (30%) and UreaGel
concentrate and UreaGel diluent were obtained by National
Diagnostics (Atlanta, GA, USA). N,N,N’,N’-tetramethylethylenedi-
amine (TEMED), ammonium persulfate (APS), 5,50-dithiobis-(2-ni-
trobenzoic acid) (DTNB) (Ellman’s reagent), L-cysteine hydrochlo-
ride monohydrate, sodium phosphate dibasic hepta-hydrate,
sodium phosphate monobasic monohydrate, Trizma base, Trizma
hydrochloride, and EDTA were obtained from Sigma-Aldrich (Co-
penhagen, Denmark). APS was prepared as 10% stock solution in
MilliQ. Gel cassettes and combs (Novex), NuPAGE, 2-(N-morpho-
lino)ethanesulfonic acid (MES), and SDS Running Buffer (20)
(Novex) were obtained from Thermo Scientiﬁc (Slangerup,
Denmark). SYBR Gold Nucleic Acid Gel Stain 10,000x was purchased
Figure 6. Representative hFcRn Binding Profiles
rHA (A), rHAODN//aptamer (B), HB (C), and HBODN//
aptamer (D). Affinity assays were performed using a 2-fold
dilution series from 3.0 to 0.1875 mM; however, for
rHAODN//aptamer (B), an additional concentration of
6.0 mM was included to obtain a sufficient signal due to
the weak hFcRn interaction. Raw data are depicted as
gray binding curves and curve fittings overlaid as a darker
thin line.
from Invitrogen (Taastrup, Denmark). Protein
assay dye reagent was obtained from Bio-Rad.
FIXa activity assay (ab204727) was purchased
from Abcam (Cambridge, UK).
Analytical and Preparative RP-HPLC
RP-HPLC was performed on an Agilent Technolo-
gies 1200 Series apparatus equipped with a C18 col-
umn (YMC-Pack Pro, 150  4.6 mm, AS-302-3,
S-3 mm, 12 nm) to verify the SMCC activation
of ODNs. A ﬂow rate of 0.7 mL/min and
UVdetection at 260 nmwere used. The productwas elutedwithA, trie-
thylammonium acetate (TEAA) 0.05M and 5%MeCN in H2O; and B,
MeCN using a gradient that was increased from 0% to 40% B over
15 min, followed by 40% to 100% B in 2 min, 2 min at 100% B, and
0% B in 3 min. Alternatively, a Kinetex C18 column and the following
buffers were used: buffer A, 0.1 M TEAA with 10% acetonitrile ﬁltered
with a 0.2-mL ﬁlter; and buffer B, 100% acetonitrile. Samples were al-
lowed to enter the column for 5 min with 100% buffer A, followed by
an increase to 90% buffer B over 30 min at RT with a ﬂow rate of
0.5 mL min1. Absorbance was measured at 260 nm as well.
Matrix-Assisted Laser Desorption/Ionization Time of Flight
Matrix-assisted laser desorption/ionization time-of-ﬂight (MALDI-
ToF) experiments were conducted on a Bruker Autoﬂex Speed.
The used matrix was 15 mg mL1 sinapic acid in a 1:1 mixture of
Milli-Q water and acetonitrile. For spotting, each drop was allowed
to dry before adding another drop. First, 2 1 mL matrix was spotted,
then 1 mL sample solution (usually 4 mM), and ﬁnally 2 mL matrix
on top.
IEX
IEX was performed using Pharmacia Biotech equipment. A Uvicors
SII detector with a detection wavelength of 226 nm, a gradient
pump 2249, a low pressure mixer, and a Degasys DG1310 degasser
were used. Recording was performed with a Pharmacia Biotech
LKB writer REC 2. The apparatus was equipped with an ion-exchange
column (MonoQ, 50  5 mm, 10-mm particles) using a ﬂow rate of
1 mL/min at RT. The product was eluted with A, 20 mM Tris-HCl
and 10 mM NaCl, pH 7.6, and B, 20 mM Tris-HCl and 0.8 M
NaCl, pH 7.6, using a gradient that was 0% B for 3 min, increased
from 0% to 100% B in 27 min, and kept at 100% B for 3 min.
B was reduced to 0% within 1 min afterward.
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SEC
SEC was performed using a Thermo Scientiﬁc Ultimate 3000 equip-
ped with a fraction collector. Detection was performed at 224 nm
using a UV-Vis detector. The apparatus was equipped with a size-
exclusion column (Zenix SEC-300, 3 mm, 300 Å, 7.8 300 mm) using
a ﬂow rate of 0.5 mL/min at RT and PBS as solvent.
Urea-Poly(acrylamide) Gel Electrophoresis
Urea gel electrophoresis was used to investigate SMCC activation
of ODN. For 30 mL, 15% polyacrylamide urea gel solution 18 mL
UreaGel concentrate, 9 mL UreaGel diluent, and 3 mL 10x Tris-
Borate-EDTA (TBE) buffer were mixed in a beaker by swirling.
100 mL APS (10%) was added and mixed, followed by 30 mL TEMED
and mixing. Urea gel electrophoresis gels were run at 150 V for 1 hr
and 45 min. Immediately after mixing the gel components, the solu-
tion was poured into gel cassettes and allowed to set for 30–60 min.
SDS-Poly(acrylamide) Gel Electrophoresis
SDS gel electrophoresis was performed using 10% gels made of Pro-
togel. Conjugation and hybridization to ODN was evaluated using
SDS gel electrophoresis. For 30 mL, 10% polyacrylamide SDS gel so-
lution 10 mL ProtoGel, 8.1 mL 1.5 M Tris, pH 8.7, 200 mL 20% SDS,
and 11.8 mL Milli-Q were mixed in a beaker by swirling. 225 mL 10%
APS was added and mixed, and ﬁnally 20 mL TEMED was added and
mixed. SDS gels were run at 150 V for 50 min. Immediately after mix-
ing the gel components, the solution was poured into gel cassettes and
allowed to set for 30–60 min. Gels were scanned using a Gel Doc EZ
Imager (Bio-Rad) or a Typhoon Trio+ (GE Healthcare). Atto488 and
SYBR Gold were detected using the 488/555 excitation/emission
settings. Coomassie was detected by colorimetry or using 633/no
bandpass excitation/emission settings. Gels were analyzed using
Image Lab (Bio-Rad) or ImageJ software.
Native Gel Electrophoresis
Native gel electrophoresis was performed with an 8% gel. For this,
2.7 mL Protogel, 6.3 mL MilliQ, 1 mL 10x TBE buffer, 100 mL 10%
APS, and 10 mL TEMED were mixed and poured into a gel cassette.
A 12-well comb was inserted and the gel was crosslinked for
45 min. For loading, 2 mL solution and 2 mL loading buffer (1.5 mL
glycerol in 10 mL MilliQ, stained with Orange G) were mixed and
4 mL were loaded into a well. The gel was run for 45 min at 150 V
with TBE buffer as running buffer. The gel was directly used for
SYBR gold staining or Coomassie staining. Gels were scanned using
a Gel Doc EZ Imager (Bio-Rad) with the corresponding ﬁlter plate.
Band analysis was performed using ImageJ.
Thiol Quantification (Ellman’s Assay)
The experiment was performed in a 96-well plate. Samples were
prepared in 100 mL volume in 0.1 M Tris-HCl, 0.01 M EDTA,
pH 8.0, containing Trizma Base and Trizma HCl in Milli-Q water.
rHA samples were analyzed in triplicates at a concentration of
62.5 mM. L-cysteine was prepared from 1 mM to 15.6 mM as
calibration. After addition of a DTNB solution (0.01 M DTNB,
0.05 M sodium phosphate buffer, pH 7.0) and 15 min incubation,
the absorbance at 412 nm was determined on a Biotek PowerWave
XS2 spectrophotometer.
Protein Quantification (Bradford Assay)
The quantiﬁcation was performed using a Bio-Rad protein assay dye
reagent following the protocol of a microassay. Brieﬂy, rHA solutions
in nuclease-free water were prepared with a concentration range of
100–2.5 mg/mL. rHA calibration solutions (8 mL) were mixed with
the pure dye concentrate (2 mL) as received. After 5 min incubation,
a NanoDrop ND1000 was used to determine the absorbance at
595 nm using the Bradford assay method. The sensor was equipped
with 2 mL solution and the absorbance was measured. This was per-
formed in triplicate, and the absorbance values were ﬁtted with a
linear trendline, giving the calibration curve. The sample solutions
were prepared with 2 mL dye and 8 mL sample solution as well, but
using a dilution of 1:10 of the original sample to obtain data that ﬁtted
the calibration range.
Protein Quantification (BCA Protein Assay)
The quantiﬁcation was performed using a Thermo Scientiﬁc Pierce
BCA Protein Assay kit following the microplate procedure. Brieﬂy,
rHA solutions in nuclease-free water were prepared with a concentra-
tion range of 1,980–123.75 mg/mL. rHA calibration solutions (10 mL)
were mixed with BCA working reagent (200 mL) in a 96-well plate.
BCA working reagent was prepared from 50 parts BCA reagent A
to 1 part BCA reagent B. The plate was covered and shaken for
60 s, followed by 60 min incubation at 37C. After cooling to RT,
a Varioskan LUX multimode microplate reader was used to deter-
mine absorbance at 562 nm. This was performed in triplicate, and
the absorbance values were ﬁtted with a non-linear least square ﬁt
giving the calibration curve. The sample solutions were prepared
with 10 mL sample mixed with 200 mL working reagent.
Maleimide Functionalization of ODNs (Activation)
Amine-modiﬁed ODN and SMCC solutions were mixed as follows:
3 parts DMSO, 2 parts 1 mM ODN, 6 parts 0.1 M HEPES adjusted
to pH 8.0, and 1 part 100 mM SMCC in DMSO. As an example,
DMSO (15 mL) was mixed with ODN (ODN3 10 mL, 1 mM,
10 nmol) in an Eppendorf tube. HEPES buffer (30 mL, 0.1 M) was
added and mixed well. Finally, SMCC (5 mL, 100 mM in DMSO,
Table 1. Biolayer Interferometry hFcRn Affinity-Binding Studies of rHA,
Annealed rHAODN//apt, hFcRn HB, and Annealed HBODN//apt
KD (mM) kon  103 (1 Ms1) koff  103 (1 s1)
rHA 0.98 ± 0.25 11.2 ± 1.96 10.6 ± 0.64
rHAODN//apt 8.80 ± 2.17 1.73 ± 0.31 14.8 ± 1.00
HB 0.10 ± 0.008 10.8 ± 0.14 1.04 ± 0.10
HBODN//apt 0.28 ± 0.08 3.32 ± 0.31 0.95 ± 0.32
The KD, kon, and koff values are averages of 3 measurements, each obtained using a
5-step dilution series from 0.1875 to 3.0 mM at pH 5.5, and for rHAODN//apt, a
6-step dilution from 0.1875 to 6.0 mM. All curves are ﬁtted to a 1:1 binding model
with the relation KD = koff/kon.
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500 nmol) was added and a white precipitate appeared (NHS). The
tube was closed and the mixture was shaken at 650 rpm overnight
at RT. For puriﬁcation, the mixture volume was increased to
200 mL with nuclease-free water and centrifuged using 14,000  g
for 10 min to collect the NHS precipitate. The supernatant was
used for RP-HPLC analysis as well as for puriﬁcation purposes using
a fraction collector. The unreacted ODN eluted at 10.5 min and
SMCC-activated ODN eluted at 11.5 min. Fractions were collected
in 260-mL portions. The fractions with the activated ODN were
collected and the material was allowed to dry out.
SMCC-ODN Conjugation to rHA
The quantity of activated SMCC-ODN was determined based on the
initial quantity used for activation and product conversion deter-
mined by RP-HPLC. The dried SMCC-activated ODN was dissolved
in nuclease-free H2O to a concentration of 80 mM. As an example,
activated ODN (conversion 50% by RP-HPLC, initial quantity
15 nmol equaling 7.5 nmol activated ODN, 1 equivalent [eq.]) was
dissolved in 93.75 mL nuclease-free H2O. rHA (10% solution [w/v],
20 mL, 30 nmol, 4 eq.) was added, and the mixture shaken at
650 rpm overnight at RT. The solution was puriﬁed from unreacted
rHA using ion-exchange chromatography. The collected fractions
were combined, and the salts were removed using a PD10 desalting
column with nuclease-free water as the equilibration buffer. The
eluted fractions were collected and the water was removed using a
Christ RVC 2-18CDplus connected to a Christ Alpha 1-2 LDplus
freeze dryer with pump.
Annealing of Complementary ODN to rHAODN Conjugates
The annealing was performed in annealing buffer (200 mM KOAc
and 2 mM EDTA in nuclease-free H2O). The conjugate solution
(10 mL, 6.3 mM in nuclease-free H2O, 63 pmol) was mixed with an-
nealing buffer (20 mL) and heated in an Eppendorf tube to 55C
for 2 min. Concurrently, the complementary strand dissolved in
nuclease-free water (10 mL, 6.3 mM in nuclease-free H2O, 63 pmol)
was heated for 2 min to 95C and cooled down to 55C. The comple-
mentary strand solution was transferred to the conjugate solution at
55C and the heater was switched off and shaken in a thermoshaker
with 650 rpm. After 60 min, the solutions were at RT and shaken
overnight. The solutions were directly analyzed using urea gel electro-
phoresis. Directly after gel electrophoresis, the gels were scanned for
the Atto488 ﬂuorophore using a Typhoon Trio+ scanner (GEHealth-
care Life Sciences) with a blue laser (488 nm) and a 526-nm band-pass
ﬁlter. Afterward, the gel was stained using standard Coomassie stain-
ing. After destaining, the gel was washed with TBE buffer three times
to remove acetic acid and methanol from the gel. SYBR gold staining
was performed according to the manufacturer’s protocol. The
Typhoon Trio+ scanner was used to scan for Coomassie staining
without ﬁlter and excitation at 633 nm (red laser) as well as SYBR
gold staining using a blue laser (488 nm) and a 555-nm band-pass
ﬁlter.
Aptamer Production
The aptamer with (cODN-aptamer) or without a 30 cODN extension
(with a 50-NH2-C6 linker and a 30- inverted deoxy-thymidine [idT])
was synthesized in a 1.0-mmol scale on a polystyrene dC support using
the phosphoramidite approach and following the manufacturer’s
standard protocols. The coupling times for the commercially available
20-deoxy-20-ﬂuoro-RNA, 20-O-methyl-RNA, 20-O-TBDMS-RNA,
and DNA phosphoramidites were 12, 16, 12, and 10 min respectively,
and stepwise coupling efﬁciencies in all cases were >98.0%, as deter-
mined by the absorbance of trityl cation at 495 nm after detritylation
using DCA in toluene (2%, v/v). DCI was used as the activator, except
for the RNA coupling, for which 1H-tetrazole was used as activator.
Cleavage from the solid support and removal of nucleobase-protect-
ing groups was performed using a solution of methyl amine in ethanol
(33%, w/w) for 12 hr at RT. After evaporation to dryness, desilylation
was performed using a 15:7:10 mixture of N-methyl-2-pyrrolidone,
triethylamine, and Et3N$3HF for 12 hr at RT. The resulting oligonu-
cleotides were puriﬁed by ion-exchange HPLC and desalted using
a NAP-10 Sephadex column (GE Healthcare) according to the
manufacturer’s instructions. The composition of the aptamer was
conﬁrmed by Maldi-MS (observed mass 13,339.8; calculated
13,339.4), and the purity as >95% by analytical ion-exchange HPLC.
Annealing of Aptamer to rHAODN
rHAODN solution (109 mM, nuclease-free water, 30 mL, 3.27 nmol)
was heated to 45C. Aptamer solution (100 mM, nuclease-free water,
30 mL, 3 nmol) was heated to 90C for 1 min. Annealing buffer (60 mL,
2x, 400 mMKOAc, and 4 mM EDTA, pH 7.6) was heated to 45C. At
45C, rHAODN solution, aptamer, and annealing buffer were mixed.
The solution was stored in the 45Cwarm heating block and the block
Figure 7. Stability of the Aptamer-Albumin Construct
in 10% Serum
The aptamer-albumin construct rHAODN//apt (A) or FIXa
aptamer (B) was incubated in 10% serum for 0, 12, and
24 hr at 37C, and the degradation was analyzed by
agarose gel electrophoresis. The DNA ladder contained 50,
100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, and
1,000 bp products. (C) Band intensity for the rHAODN//apt
construct and the FIXa aptamer at each time point was
quantified, and the average of three independent experi-
ments is shown relative to the 0 time point. Error bars
show SD.
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was turned off. After cooling down to RT, the solution was stored at
4C overnight. The solution was subjected to SEC puriﬁcation, and
collected fractions were concentrated using Amicon Ultra 0.5 mL
centrifugal ﬁlters with a Nominal Molecular Weight Limit of 3,000.
500 mL eluted fraction was loaded into the ﬁlter device and spun at
14,000  g for 10 min, performed over several sittings. The concen-
trated samples were recovered from the spin ﬁlter by reverse spin
at 1,000  g for 2 min. For biolayer interferometry, samples were
washed one time with 500 mL nuclease-free water prior to recovery.
Concentrated samples were analyzed using SDS and native gel elec-
trophoresis. Coomassie and SYBR gold staining was used to visualize
the protein and nucleic acids, respectively.
FIXa Activity Assay
The protocol provided by Abcam for FIXa activity was slightly modi-
ﬁed. Experiments were performed in triplicate. In a 96-well plate
(transparent bottom, black), 10 mL of a FIXa enzyme standard
(4 pg/mL enzyme standard in assay buffer) was placed in every well
except the blank wells that were ﬁlled with 10 mL PBS. cODN-ap-
tamer, rHAODN, and rHAODN//apt solutions were prepared in
PBS (100 nM, 10 nM, and 1 nM). For each well, 10 mL of each solution
was mixed with 78 mL of assay buffer. These 88-mL portions were
mixed thoroughly with the prior pipetted FIXa enzyme in the wells.
For untreated control, 10 mL PBS was mixed with 78 mL assay buffer
and mixed with the enzyme-containing wells. The wells left for blank
(no enzyme) were also mixed with this 10 mL PBS/78 mL assay buffer
mix per each well. The 96-well plates were incubated at 37C for
15 min to allow FIXa:aptamer binding. To each well, 10 mL Reaction
Mix (2 mL Enzyme Mix I, 6 mL phospholipids, and 2 mL Enzyme Mix
II) was added and incubated for 15 min at 37C. After incubation,
2 mL FXa substrate-AMC was mixed in each well. At 37C the ﬂuo-
rescence development (excitation/emission [ex/em] = 360/450 nm)
was recorded in kinetic mode on a Varioskan LUXmultimode micro-
plate reader. The samples were scanned every 2 min for 120 min. For
data processing, the average blanks were subtracted from the values
obtained for the samples. Relative ﬂuorescent units (RFU) were
plotted against time. Linear region of the ﬂuorescence development
was used for data analysis. The slope of the RFU development shows
the activity of the FIXa enzyme able to produce FXa that cleaves the
chromogenic substrate.
hFcRn Binding Studies
A BLItz system (ForteBio, Pall Life Sciences, Menlo Park, CA, USA)
was used with hFcRn-immobilized biosensors attached by streptavi-
din-biotin interactions. The streptavidin biosensors were hydrated
in PBS supplemented with 0.01% Tween 20 (PBST) (pH 7.4) for
a minimum of 10 min prior to coating. Biotinylated hFcRn (Immuni-
track ApS) diluted in PBST (pH 7.4) to 3 mg mL1 was used for
coating and washed in PBST (pH 7.4). Albumin or aptamer albumin
construct binding was measured using association buffer (25 mM so-
dium acetate, 25 mM NaH2PO4, and 150 mMNaCl in PBST, pH 5.5)
with increasing sample concentrations (0.1875, 0.375, 0.75, 1.5, and
3.0 mM). The association step lasted for 120 s, and the dissociation
step lasted for 300 s. Sensor regeneration was performed in PBST
(pH 7.4) in between measurements. Background was subtracted for
all binding curves using a reference run in pure association buffer.
Analysis was performed using the BLItz Pro 1.2 software, and data
were ﬁtted to a 1:1 binding model.
Serum Stability Assays
10 pmol of FIXa aptamer, cODN-aptamer (apt), rHAODN, rHA, or
rHAODN//apt was incubated in 10 mL of 20 mM HEPES (pH 7.4)
containing 140 mM NaCl and 10% fetal calf serum (Sigma-Aldrich)
for 0, 12, and 24 hr at 37C. Samples were then analyzed by 1.5%
agarose gel electrophoresis using 1xTBE as running buffer and
SYBR Gold in the gel. The DNA ladder used was the Generuler
50-bp DNA ladder (Thermo Fisher Scientiﬁc). Gels were scanned
using the Gel Doc EZ Imager, and quantiﬁcation of gel band intensity
was performed with ImageJ.
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